For example, the combination regimen of paclitaxel and albumin-bound paclitaxel with immune checkpoint inhibitors (such as Socazolimab, Tislelizumab, Avelumab) or targeted drugs (such as trastuzumab analogs, everolimus) in the neoadjuvant or first-line treatment of advanced urothelial carcinoma and MIBC showed a good synergistic effect and clinical activity [54,56,61], especially providing an effective option for cisplatin-unfit patients. The gene discussed is ALB; the disease is urothelial carcinoma.